Difficulties breathings; covid-19; Sore throat; Itching in the chest; allergy like symptoms; had pain in her arm; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat), DYSPNOEA (Difficulties breathings), PRURITUS (Itching in the chest), HYPERSENSITIVITY (allergy like symptoms) and VACCINATION SITE PAIN (had pain in her arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included RA.    On 15-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2021, the patient experienced VACCINATION SITE PAIN (had pain in her arm). On 18-Oct-2021, the patient experienced PRURITUS (Itching in the chest) and HYPERSENSITIVITY (allergy like symptoms). On 25-Oct-2021, the patient experienced OROPHARYNGEAL PAIN (Sore throat). On 03-Nov-2021, the patient experienced DYSPNOEA (Difficulties breathings). 03-Nov-2021, the patient experienced COVID-19 (covid-19). The patient was treated with OSELTAMIVIR PHOSPHATE for Adverse event, at a dose of 75 mg. In October 2021, PRURITUS (Itching in the chest) and HYPERSENSITIVITY (allergy like symptoms) had resolved. At the time of the report, OROPHARYNGEAL PAIN (Sore throat), DYSPNOEA (Difficulties breathings), VACCINATION SITE PAIN (had pain in her arm) and COVID-19 (covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Nov-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient was prescribed XR11 for Rheumatoid arthritis.  Doctor also prescribed monoclonal antibody therapy.  This spontaneous case concerns a female patient with no relevant medical history reported, who experienced non-serious unexpected event of special interest (AESI) dyspnoea and COVID-19. The events occurred 19 days after the first dose of the Moderna COVID-19 Vaccine (mRNA-1273). Initially, the patient experienced allergy like symptoms and sore throat. One week later, the patient experienced dyspnoea and tested positive for COVID-19. Rechallenge was not applicable since outcome of the events was unknown and there is no information regarding second dose so, no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report.; Sender's Comments: This spontaneous case concerns a female patient with no relevant medical history reported, who experienced non-serious unexpected event of special interest (AESI) dyspnoea and COVID-19. The events occurred 19 days after the first dose of the Moderna COVID-19 Vaccine (mRNA-1273). Initially, the patient experienced allergy like symptoms and sore throat. One week later, the patient experienced dyspnoea and tested positive for COVID-19. Rechallenge was not applicable since outcome of the events was unknown and there is no information regarding second dose so, no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report.